Urgent.News

What's breaking now, across thousands of outlets.

Business

Samsung Biologics Secures 87.8% Stake in Polypeptide

Samsung Biologics has passed a decisive hurdle to acquire Polypeptide Group, a global peptide contract development and manufacturing organization (CDMO). As the preliminary results of the tender offer showed that the tendered stake significantly exceeded the minimum acceptance condition, the company

We haven't written up this one. BusinessKorea has the full story — the link below goes straight to it.

Read the original at businesskorea.co.kr →

More in Business

More from Tuesday 13 October →